These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7512464)

  • 21. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The treatment of renal hypertension with verapamil in childhood (author's transl].
    Schärer K; Alatas H; Bein G
    Monatsschr Kinderheilkd (1902); 1977 Jul; 125(7):706-12. PubMed ID: 895736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Verapamil deleterious effects in chronic renal failure.
    Váquez C; Huelmos A; Alegría E; Errasti P; Purroy A
    Nephron; 1996; 72(3):461-4. PubMed ID: 8852497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new sustained-release formulation of verapamil in the treatment of hypertension.
    Midtbo KA; Hals O; Lauve O
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation.
    Di Somma S; Carotenuto A; de Divitiis M; Paulucci A; Galderisi M; Cuocolo A; de Divitiis O
    J Hum Hypertens; 1995 Mar; 9(3):163-8. PubMed ID: 7783096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-invasive haemodynamic study in hypertensive subjects after treatment with verapamil slow release.
    Vulpis V; Seccia TM; Ricci S; Lograno MD; Daniele E; Pirrelli A
    Pharmacol Res; 1994; 30(2):153-60. PubMed ID: 7816743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nadolol on systemic and renal hemodynamics in patients with renoparenchymal hypertension and various degrees of renal function.
    Valvo E; Gammaro L; Bedogna V; Cavaggioni M; Tonon M; Lupo A; Loschiavo C; Tessitore N; Oldrizzi L; Rugiu G
    Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):202-6. PubMed ID: 3710633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results with verapamil in essential hypertension and its influence on serum lipids.
    Lewis GR
    Am J Cardiol; 1986 Feb; 57(7):35D-38D. PubMed ID: 3513514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of intravenous verapamil in arterial hypertension refractory to three-step antihypertensive therapy.
    Gurgenian SV; Mikaelian ES; Dzhandzhapanian AZ; Babaian AS
    Cor Vasa; 1991; 33(5):397-403. PubMed ID: 1810700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension.
    Lambertucci L; Di Serio C; Castellani S; Torrini M; Lotti E; Cristofari C; Masotti G; Marchionni N; Ungar A
    Transl Res; 2011 Jun; 157(6):348-56. PubMed ID: 21575919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antihypertensive therapy in renal failure].
    Mayer G
    Acta Med Austriaca; 1995; 22(3):51-3. PubMed ID: 8571752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
    Reynolds NA; Wagstaff AJ; Keam SJ
    Drugs; 2005; 65(13):1893-914. PubMed ID: 16114984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of nifedipine GITS on renal function in hypertensive patients with renal insufficiency.
    Reams G; Lau A; Knaus V; Bauer JH
    J Clin Pharmacol; 1991 May; 31(5):468-72. PubMed ID: 2050834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of verapamil on renal haemodynamics in a portal hypertensive rat model.
    Lay CS; Yang MC; Wu SL; Tsai YT; Wu KL; Chien S
    J Gastroenterol Hepatol; 1996 Apr; 11(4):391-5. PubMed ID: 8713708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.
    Frishman WH; Eisen G; Charlap S; Strom JA
    J Clin Hypertens; 1987 Dec; 3(4):605-9. PubMed ID: 3134517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy with ACE inhibitors in chronic heart failure and limited kidney function].
    Osterziel KJ; Nagel F; Dietz R
    Z Kardiol; 1994; 83 Suppl 4():81-7. PubMed ID: 7856286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibitors in chronic renal failure.
    Opsahl JA; Abraham PA; Keane WF
    Drugs; 1990; 39 Suppl 2():23-32. PubMed ID: 2188823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related antihypertensive and haemodynamic effects of verapamil SR: clinical results and effects on atrial natriuretic peptide.
    Antonicelli R; Tomassini PF; Galletti P; Gambini C; Marini M; Amadio L; Paciaroni E
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S29-33. PubMed ID: 2148149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic and renal hemodynamic changes after two-month treatment with enalapril in patients with essential hypertension.
    Valvo E; Gammaro L; Bedogna V; Tonon M; Giorgetti P; Pica B; Antonini P; Tessitore N; Oldrizzi L; Rugiu C
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):656-9. PubMed ID: 2830196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.